IPP Bureau
Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
By IPP Bureau - February 21, 2025
Wanbury reports 88% drop in Q3 FY25 PAT
By IPP Bureau - February 21, 2025
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
By IPP Bureau - February 21, 2025
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
USFDA classifies Aurobindo Pharma Inc's warehouse as OAI
By IPP Bureau - February 21, 2025
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
By IPP Bureau - February 21, 2025
The inspection was successfully completed
European Commission approves Biocon Biologics' Ustekinumab Biosimilar
By IPP Bureau - February 21, 2025
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Lupin receives EIR from USFDA for its Somerset manufacturing facility
By IPP Bureau - February 21, 2025
the inspection conducted from January 27 to January 31, 2025
USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
By IPP Bureau - February 21, 2025
Observations are largely around improvement of procedures and practices
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
By IPP Bureau - February 20, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
By IPP Bureau - February 20, 2025
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innocan Pharma granted first patent in India for its Liposomal CBD Injection
By IPP Bureau - February 20, 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD showcases ‘Skinification’ trend at HPCI India 2025
By IPP Bureau - February 19, 2025
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Merck’s Welireg receives European approval for two indications
By IPP Bureau - February 19, 2025
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
KIMS partners with UAIMS Hospital
By IPP Bureau - February 19, 2025
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025
By IPP Bureau - February 19, 2025
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
